Source: International Congress 2014 – Pathobiology of pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Price, D. Shao, C. Meng, F. Perros, D. Montani, P. Dorfmuller, M. Humbert, I. Adcock, J. Wort (London, United Kingdom; Paris, France). Nuclear factor-kappa B inhibition exerts anti-remodelling effects in pulmonary arterial smooth muscle cells. Eur Respir J 2014; 44: Suppl. 58, 2944

Member's Comments

No comment yet.

Related content which might interest you: Obligatory role of MEK/ERK/RSK90 in the mitogenic responses of human pulmonary artery smooth muscle cells Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Nuclear IL-33 arguments ST2 receptor expression in pulmonary arterial endothelial cells: Implication in the pathogenesis and progression of pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Comparison of current therapies against endothelin-induced growth in pulmonary smooth arterial muscle cells (PASMCs) derived from patients with pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Role of NMDA receptors in vascular remodelling associated to pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Smooth muscle microparticles as novel biomarkers of vascular remodelling and inflammation in pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Neuron-derived orphan receptor 1 mediated human pulmonary arterial smooth muscle cells proliferation via cyclin D1 Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Inflammasome ASC-knock out attenuates the development of pulmonary hypertension caused by chronic alveolar hypoxia Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Insulin-like growth factor-1 contributes to the pulmonary artery smooth muscle cell proliferation in pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 ASK1 promotes maladaptive remodeling in a rodent model of pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Endothelial microparticles and progenitor cells in pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Acid sphingomyelinase, a novel pathway for pulmonary vasoconstriction. Activation by apoptotic T cell microparticles and Fas ligand Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Characterization of circulating CD133+ progenitor cells in pulmonary arterial hypertension Source: International Congress 2014 – Pathobiology of pulmonary hypertension Year: 2014 Prevention of monocrotaline-induced pulmonary vascular and myocardial remodeling by the selective neutrophil elastase inhibitor BAY 85-8501 Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 The flavonoid quercetin reverses monocrotaline-induced pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Vascular endothelial growth factor (VEGF) as marker of pulmonary hypertension in children with asthma Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Anti-contractile and anti-proliferative responses in human pulmonary arterial smooth muscle cells induced by ACT-333679, the active metabolite of selexipag, a non-prostanoid selective prostacyclin receptor agonist Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 M2 macrophages derived from patients with idiopathic pulmonary arterial hypertension are susceptible for apelin-mediated suppression of pro-inflammatory cytokines Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Muscle function and physical activity in patients with idiopathic pulmonary arterial hypertension (IPAH) Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 LSC 2014 abstract - Combined effects of inflammatory mediators and BMPR2 mutation on pulmonary arterial cell function in a pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Th17 inflammation and pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014